Evidence map›Paper›PMID 36204922›Full record

ArticleAnnals of African medicine

Retinal Toxicity from Chronic Hydroxychloroquine use in Kenya.

Oscar M Onyango, Sarah M Sitati

Open access · greenAbstract readCase Reports
In one paragraph

Article in Annals of African medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Oscar M OnyangoDepartment of Ophthalmology, Kenyatta National Hospital, Nairobi, Kenya.
Sarah M SitatiDepartment of Ophthalmology, Kenyatta National Hospital, Nairobi, Kenya.
Kenyatta National Hospital · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irreversible visual loss due to retinal toxicity is one of the side effects of hydroxychloroquine (HCQ) therapy. The recent outbreak of the novel coronavirus-19 (COVID 19) has seen HCQ proposed as a possible treatment and prophylactic drug, leading to its increased use. Many are unaware of its ocular side effects. We describe a case of HCQ-induced retinopathy in a 46-year-old female who was referred by a rheumatologist for routine eye review.

Indexed as

Antirheumatic AgentsCOVID-19 Drug TreatmentRetinal DiseasesFemaleHumansHydroxychloroquineKenyaMiddle AgedRetinaTomography, Optical CoherenceAntirheumatic AgentsHydroxychloroquineHydroxychloroquineretinaretina toxicityretinopathy

Identifiers

PMID36204922
PMCPMC9671192
OpenAlexW4303513606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.